Medicis Pharmaceutical Corp. (MRX) Reports Slightly Better-Than-Expected Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $69.96 +2.07%
EPS Growth %: +27.1%
Financial Fact:
Income from continuing operations: 937K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +27.1%
Financial Fact:
Income from continuing operations: 937K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q4 EPS of $0.56, $0.01 better than the analyst estimate of $0.55. Revenue for the quarter came in at $180.7 million versus the consensus estimate of $179.2 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Top restaurant stocks to watch, according to Raymond James
- Wells Fargo Names Top Pick Ahead of Q3 Earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
